liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Microscopic colitis: Current status, present and future challenges Statements of the European Microscopic Colitis Group
Linköpings universitet, Institutionen för klinisk och experimentell medicin, Gastroenterologi och hepatologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Hjärt- och Medicincentrum, Endokrin- och magtarmmedicinska kliniken US.
University Hospital, Dresden, Germany.
Örebro University Hospital, Sweden and University of Örebro, Sweden .
Regional Hospital Silkeborg, Denmark .
Vise andre og tillknytning
2012 (engelsk)Inngår i: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 6, nr 9, s. 932-945Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Microscopic colitis (MC) is an inflammatory bowel disease presenting with chronic, non-bloody watery diarrhoea and few or no endoscopic abnormalities. The histological examination reveals mainly two subtypes of MC, lymphocytic or collagenous colitis. Despite the fact that the incidence in MC has been rising over the last decades, research has been sparse and our knowledge about MC remains limited. Specialists in the field have initiated the European Microscopic Colitis Group (EMCG) with the primary goal to create awareness on MC. The EMCG is furthermore a forum with the intention to promote clinical and basic research. In this article statements and comments are given that all members of the EMCG have considered being of importance for a better understanding of MC. The paper focuses on the newest updates in epidemiology, symptoms and diagnostic criteria, pathophysiology and highlights some unsolved problems. Moreover, a new treatment algorithm is proposed on the basis of new evidence from well-designed, randomized control trials.

sted, utgiver, år, opplag, sider
Elsevier , 2012. Vol. 6, nr 9, s. 932-945
Emneord [en]
Microscopic colitis, Collagenous colitis, Lymphocytic colitis, Budesonide
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-85622DOI: 10.1016/j.crohns.2012.05.014ISI: 000309990400009OAI: oai:DiVA.org:liu-85622DiVA, id: diva2:572067
Merknad

Funding Agencies|Tillots Pharma||Falk Pharma||Tillotts Pharma||Ferring||MSD||Astra-Zeneca||Falk Foundation, Germany||MEDA, Sweden||

Tilgjengelig fra: 2012-11-26 Laget: 2012-11-26 Sist oppdatert: 2017-12-07

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekst

Personposter BETA

Münch, AndreasHjortswang, HenrikStröm, Magnus

Søk i DiVA

Av forfatter/redaktør
Münch, AndreasHjortswang, HenrikStröm, Magnus
Av organisasjonen
I samme tidsskrift
Journal of Crohn's & Colitis

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 140 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf